Mirnas As Biomarkers of Adverse Drug Reactions to Platinum-Based Agents in Patients with Non-Small-Cell Lung Cancer

Vasconcelos, Pedro Ens; Visacri, Marília Berlofa; Pincinato, Eder de Carvalho; Torso, Nadine de Godoy; Seguin, Cecília S; Zambon, Lair; Barbeiro, Aristóteles de Souza; Wp, Maurício; Moriel, Patrícia

doi:10.2217/bmm-2021-0443

Cited by 1 publication

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prognostic biomarkers should aid in the decision to justify highly toxic chemotherapy. Our research group previously performed a scope review that assessed the possible associations between adverse reactions to chemotherapy and circulating miRNAs in patients with NSCLC; however, only one article was identified that met the inclusion criteria, which indicated a substantial lack of data in this area (19). To the best of our knowledge, the present study is the first to evaluate plasma miRNAs as possible biomarkers of adverse hematological reactions in patients with NSCLC.…”

Section: Introductionmentioning

confidence: 96%

hsa‑miR‑455‑3P as a predictive biomarker of anemia in patients with non‑small cell lung cancer treated with carboplatin plus paclitaxel

Vasconcelos,

Seguin,

Barbeiro

et al. 2024

Oncol Lett

Self Cite

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. The initial treatment of lung cancer depends on the definition of the tumor type and its staging. The most common treatment is chemotherapy, and the first-line treatment is a combination of carboplatin and paclitaxel. Although this treatment has good efficacy, there is a high prevalence of adverse events, particularly hematological reactions. Studies on new biomarkers related to these adverse events, such as circulating microRNAs (miRNAs/miRs), are important for optimizing the quality of life of patients. miRNAs have high stability in several biological fluids and they have specific expressions in different tissues or pathologies. Thus, the present study aimed to assess the relationship between circulating miRNAs and adverse hematologic reactions caused by treatment with carboplatin + paclitaxel in patients with lung cancer. Blood was collected from patients before and 15 days after chemotherapy for hematological adverse reaction analysis, microarray and quantitative (q)PCR validation. Adverse reactions were classified according to the Common Terminology Criteria for Adverse Events v4.0. Microarray analysis was performed using plasma from six patients without anemia and six patients with anemia, and nine miRNAs were differentially expressed. miR-1273g-3p, miR-3613-5p and miR-455-3p, identified using microarray, were assessed using qPCR in 20 patients without anemia and 26 patients with anemia. Bioinformatic analyses of miR-455-3p were performed using miRWalk, the Database for Annotation, Visualization and Integrated Discovery and GeneMania software. Microarray analysis of patients with and without anemia revealed nine significant differentially-expressed plasma miRNAs among these patients. Of these, miR-1273g-3p, miR-3613-5p and miR-455-3p were chosen for further assessment. Only miR-455-3p demonstrated a significant reduction in expression (P=0.04) between the groups before chemotherapy with carboplatin + paclitaxel. Bioinformatics analysis of miR-455-3p revealed a relationship between this miRNA and the hematopoietic pathway, particularly with respect to the RUNX family transcription factor 1 (RUNX1) and TAL bHLH transcription factor 1, erythroid differentiation factor (TAL1) genes. The most prevalent adverse reactions in patients with lung cancer treated with carboplatin + paclitaxel were hematological, particularly anemia. This adverse reaction, caused by dysfunction of the hematopoietic system, may be explained by a possible association between the important genes in this system, RUNX1 and TAL1, and hsa-miR-455-3p.

show abstract

Section: Introductionmentioning

confidence: 96%